Rick Modi, Affinia Therapeutics CEO (Affinia)

Gene ther­a­py play­er Affinia aims to go pub­lic, hop­ing to raise big mon­ey in ef­fort to re­make AAVs

Nine months af­ter Affinia Ther­a­peu­tics raised $110 mil­lion in a Se­ries B, the biotech has set its eyes on the Nas­daq.

The MA-based pre­clin­i­cal gene ther­a­py biotech, which got $60 mil­lion in start­up cap­i­tal from New En­ter­prise As­so­ciates, F-Prime and At­las in 2019, filed an S-1 with the SEC on Tues­day, an­nounc­ing ini­tial plans to go pub­lic and pen­cil­ing in a $100 mil­lion raise. Affinia plans to list un­der the tick­er $AF­TX.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.